Clinical Coagulation, Malmö

561 – 570 of 659

show: 10
|
sort: year (new to old)

News feed Embed this list Save this search Mark all Export

Cancel

Embed this list

copy and paste the html snippet below into your own page:

<iframe src="https://lup.lub.lu.se/search/organization/V1000575?embed=1&amp;hide_pagination=1&amp;hide_info=1&amp;hide_options=1"
  width="100%"
  height="400"
  allowtransparency="true"
  frameborder="0">
</iframe>

« previous
1
…
56
57
58
59
…
66
next »

2003
Mark The pharmacokinetics of clotting factor therapy.
Berntorp, Erik ^LU and Björkman, S (2003) In Haemophilia 9(4). p.353-359
- Contribution to journal › Article
Mark Prophylactic therapy for haemophilia: early experience.
Berntorp, Erik ^LU (2003) In Haemophilia 9 Suppl 1. p.41403-41403
- Contribution to journal › Article
Mark On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome.
Steen Carlsson, Katarina ^LU ; Höjgård, Sören ^LU ; Glomstein, A. ; Lethagen, Stefan ^LU ; Schulman, S. ; Tengborn, Lilian ^LU ; Lindgren, Anna ^LU ; Berntorp, Erik ^LU and Lindgren, Björn ^LU (2003) In Haemophilia 9(5). p.555-566
- Contribution to journal › Article
Mark Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay
Turecek, PL ; Varadi, K ; Keil, B ; Negrier, C ; Berntorp, Erik ^LU ; Astermark, Jan ^LU ; Bordet, JC ; Morfini, M ; Linari, S and Schwarz, HP (2003) In Pathophysiology of Haemostasis and Thrombosis 33(1). p.16-22
- Contribution to journal › Article
Mark Experience with a new percutaneous port system, Percuseal(R), for intravenous injection in patients with haemophilia, von Willebrand disease and severe alpha1-antitrypsin deficiency.
Berntorp, Erik ^LU ; Piitulainen, Eeva ^LU ; Lethagen, Stefan ^LU ; Mattson, E ; Tengborn, Lilian ^LU and Mätzsch, Thomas ^LU (2003) In Haemophilia 9(2). p.173-178
- Contribution to journal › Article
Mark Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro.
Astermark, Jan ^LU ; Voorberg, J. ; Lenk, H. ; DiMichele, D. ; Shapiro, A. ; Tjönnfjord, G. and Berntorp, Erik ^LU (2003) In Haemophilia 9(5). p.567-572
- Contribution to journal › Article
Mark When to start and when to stop primary prophylaxis in patients with severe haemophilia.
Astermark, Jan ^LU (2003) In Haemophilia 9(Suppl 1). p.32-36
- Contribution to journal › Article
Mark Consensus perspectives on prophylactic therapy for haemophilia: summary statement.
Berntorp, Erik ^LU ; Astermark, Jan ^LU ; Björkman, S ; Blanchette, V. S. ; Fischer, K. ; Giangrande, P. L. F. ; Gringeri, A. ; Ljung, Rolf ^LU ; Manco-Johnson, M. J. and Morfini, M. , et al. (2003) In Haemophilia 9(Suppl 1). p.41278-41278
- Contribution to journal › Letter
Mark Elective orthopaedic surgery for inhibitor patients.
Rodriguez-Merchan, E. C. ; Wiedel, J. D. ; Wallny, T. ; Hvid, I. ; Berntorp, Erik ^LU ; Rivard, G-E ; Goddard, N. J. ; Querol, F. and Caviglia, H. (2003) In Haemophilia 9(5). p.625-631
- Contribution to journal › Article
Mark Tailored pharmacokinetic dosing allows self-administration and reduces the cost of IV augmentation therapy with human alpha(1)-antitrypsin.
Piitulainen, Eeva ^LU ; Bernspång, Elisabeth ^LU ; Björkman, Sven and Berntorp, Erik ^LU (2003) In European Journal of Clinical Pharmacology 59(2). p.151-156
- Contribution to journal › Article

« previous
1
…
56
57
58
59
…
66
next »